Guardant Health Unveils Data on Liquid Biopsy Tests for Breast Cancer at SABCS 2025

Reuters12-05

Guardant Health Unveils Data on Liquid Biopsy Tests for Breast Cancer at SABCS 2025

Guardant Health Inc. announced that it will present 14 abstracts at the 2025 San Antonio Breast Cancer Symposium, taking place December 9-12, 2025. The presentations will include results from studies utilizing Guardant Reveal, the company's tissue-free test for detecting minimal residual disease (MRD), and Guardant360 Liquid, a comprehensive multiomic profiling test. Highlights include data demonstrating the clinical utility of Guardant Reveal in predicting outcomes for patients with early-stage HER2-positive breast cancer, with early circulating tumor DNA (ctDNA) clearance during treatment associated with improved outcomes. The company's findings underscore the potential of blood-based, non-invasive testing to inform treatment selection and patient management across early and metastatic breast cancer settings. Results from these studies will be presented at the upcoming symposium.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251205429209) on December 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589919897?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-05 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589919897","market":"nz","top_or_hot":-1,"title":"Guardant Health Unveils Data on Liquid Biopsy Tests for Breast Cancer at SABCS 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Guardant Health Unveils Data on Liquid Biopsy Tests for Breast Cancer at SABCS 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/GH\">Guardant Health Inc.</a> announced that it will present 14 abstracts at the 2025 San Antonio Breast Cancer Symposium, taking place December 9-12, 2025. The presentations will include results from studies utilizing Guardant Reveal, the company's tissue-free test for detecting minimal residual disease (MRD), and Guardant360 Liquid, a comprehensive multiomic profiling test. Highlights include data demonstrating the clinical utility of Guardant Reveal in predicting outcomes for patients with early-stage HER2-positive breast cancer, with early circulating tumor DNA (ctDNA) clearance during treatment associated with improved outcomes. The company's findings underscore the potential of blood-based, non-invasive testing to inform treatment selection and patient management across early and metastatic breast cancer settings. Results from these studies will be presented at the upcoming symposium.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251205429209) on December 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Guardant Health Unveils Data on Liquid Biopsy Tests for Breast Cancer at SABCS 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGuardant Health Unveils Data on Liquid Biopsy Tests for Breast Cancer at SABCS 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-05 21:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Guardant Health Unveils Data on Liquid Biopsy Tests for Breast Cancer at SABCS 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/GH\">Guardant Health Inc.</a> announced that it will present 14 abstracts at the 2025 San Antonio Breast Cancer Symposium, taking place December 9-12, 2025. The presentations will include results from studies utilizing Guardant Reveal, the company's tissue-free test for detecting minimal residual disease (MRD), and Guardant360 Liquid, a comprehensive multiomic profiling test. Highlights include data demonstrating the clinical utility of Guardant Reveal in predicting outcomes for patients with early-stage HER2-positive breast cancer, with early circulating tumor DNA (ctDNA) clearance during treatment associated with improved outcomes. The company's findings underscore the potential of blood-based, non-invasive testing to inform treatment selection and patient management across early and metastatic breast cancer settings. Results from these studies will be presented at the upcoming symposium.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251205429209) on December 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4551","symbol_name":"寇图资本持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL7RxRJS:1","article_id":"2589919897","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589919897","pubTimestamp":1764939921,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Guardant Health Inc. announced that it will present 14 abstracts at the 2025 San Antonio Breast Cancer Symposium, taking place December 9-12, 2025. The presentations will include results from studies utilizing Guardant Reveal, the company's tissue-free test for detecting minimal residual disease , and Guardant360 Liquid, a comprehensive multiomic profiling test. Highlights include data demonstrating the clinical utility of Guardant Reveal in predicting outcomes for patients with early-stage HER2-positive breast cancer, with early circulating tumor DNA  clearance during treatment associated with improved outcomes. The company's findings underscore the potential of blood-based, non-invasive testing to inform treatment selection and patient management across early and metastatic breast cancer settings. Results from these studies will be presented at the upcoming symposium.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT s","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4551":"寇图资本持仓","BK4588":"碎股","BK4196":"保健护理服务","BK4585":"ETF&股票定投概念","BK4535":"淡马锡持仓","GH":"Guardant Health Inc."},"translate_title":"Guardant Health在SABCS 2025上公布乳腺癌液体活检测试数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GH":0.9},"content_text":"Guardant Health Unveils Data on Liquid Biopsy Tests for Breast Cancer at SABCS 2025\n    \n\nGuardant Health Inc. announced that it will present 14 abstracts at the 2025 San Antonio Breast Cancer Symposium, taking place December 9-12, 2025. The presentations will include results from studies utilizing Guardant Reveal, the company's tissue-free test for detecting minimal residual disease (MRD), and Guardant360 Liquid, a comprehensive multiomic profiling test. Highlights include data demonstrating the clinical utility of Guardant Reveal in predicting outcomes for patients with early-stage HER2-positive breast cancer, with early circulating tumor DNA (ctDNA) clearance during treatment associated with improved outcomes. The company's findings underscore the potential of blood-based, non-invasive testing to inform treatment selection and patient management across early and metastatic breast cancer settings. Results from these studies will be presented at the upcoming symposium.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251205429209) on December 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589919897","isCrawlerRequest":true}